Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — Investor Presentation (September 2018)
27 slides from Emmaus Life Sciences's investor presentation, Sep 6, 2018
Slide 1: Greater Access to More Effective Treatments Reduces Total Cost of Care
GREATER ACCESS TO MORE EFFECTIVE TREATMENTS REDUCES TOTAL COST OF CARE September 2018 Investor Presentation NASDAQ: MYND
Slide 2: Disclaimer
Investor Presentation DISCLAIMER This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, comp
Slide 3: MYnd Analytics: Telemedicine and Data Analytics
Investor Presentation 3 MYND ANALYTICS (NASDAQ:MYND) Telemedicine Data Analytics/ Machine Learning Unique early advantage in effectively treating mental health conditions through the combination of telemedicine and data analytics/ artificial (augmented) intelligence to improve health care delivery a
Slide 4: Investment Highlights
Investor Presentation 4 INVESTMENT HIGHLIGHTS x Initial focus is the $147 billion underserved mental health market 1 o Highest worldwide disease burden and single largest reason for work disability o Over $8k additional yearly health care costs for individuals not adequately treated for co - morbid
Slide 5: Mental Health - Today
Investor Presentation 5 MENTAL HEALTH - TODAY Problem : • There is a shortage of psychiatrists so most treatment for non - psychotic mental health disorders is delivered by non - psychiatrists. 2 • Clinicians often rely on trial and error prescribing for depression, anxiety, PTSD and other mental he
Slide 6: Digital Health Care: Investments
Investor Presentation DIGITAL HEALTH CARE: INVESTMENTS MYND is in one of the hottest areas of AI/digital health care 6 1/16 - 8/16
Slide 7: How Does MYnd Improve Access to Care: Arcadian
Investor Presentation 7 HOW DOES MYND IMPROVE ACCESS TO CARE: ARCADIAN • Arcadian specializes in the delivery of mental health services through a network of social workers, therapists and psychiatrists throughout the United States • Offers a suite of services including telepsychiatry, teletherapy, d
Slide 8: Telepsychiatry
Investor Presentation 8 TELEPSYCHIATRY • Telepsychiatry involves the use of video conferencing and telecommunication equipment to conduct real time mental health consultation between a clinician and patient • Ideal for individuals living in underserved areas or those with limited access to services,
Slide 9: How Does PEER Improve Treatment Efficacy
Investor Presentation 9 HOW DOES PEER IMPROVE TREATMENT EFFICACY • An electroencephalogram (EEG) is a completely painless, non - invasive test that records your brain’s electrical activity and provides a basis for comparison against others within the Psychiatric Electroencephalography Evaluation Reg
Slide 10: Clinical Evidence for PEER
Investor Presentation 10 CLINICAL EVIDENCE FOR PEER Independent studies • 45 studies with 3 , 130 patients offer compelling evidence for QEEG biomarkers as simple, inexpensive predictors of patient response to specific antidepressants and likely treatment - related side effects (including suicidal i
Slide 11: What Doctors Say
Investor Presentation 11 WHAT DOCTORS SAY “Why are we treating an organ, the brain, without measuring the effect of our treatment on the organ? There are over 100 medications available for the treatment of behavioral disorders. The core problem is not that we need three more, the problem is that we
Slide 12: Potential Utilizers of Services: VA/Military, Managed Care
Investor Presentation 12 POTENTIAL UTILIZERS OF SERVICES VA/Military Where suicide rates are high and need for innovative and effective mental health care is high Managed Care Payers and health systems seeking to improve clinical outcomes and lower health care costs Case study : Horizon Healthcare S
Slide 13: Potential Utilizers of Services: Provider Direct
Investor Presentation 13 POTENTIAL UTILIZERS OF SERVICES Provider Direct Multi - practitioner provider groups seeking to provide value - based care and cutting edge objective measurement tools that are reimbursed Multi - Practice Groups Over 15% of patients have mental health concerns but expertise
Slide 14: Recent Developments
Investor Presentation RECENT DEVELOPMENTS Recent partnerships illustrate highly scalable business model : x Launched school - based telepsychiatry program designed to provide youths with improved access to mental health services o Partnering activities with school districts and universities underway
Slide 15: Experienced Leadership
Investor Presentation EXPERIENCED LEADERSHIP Board of Directors George C. Carpenter, IV – President & CEO • Over 25 years of experience in healthcare technology and business development • MBA in Finance from the University of Chicago, BA from Dartmouth College Brian MacDonald – Chief Technology Offi
Slide 16: 2018 Milestones
Investor Presentation 16 2018 MILESTONES 1 Establish 2 nd paid pilot program(s) with managed care companies or health systems seeking to improve clinical outcomes and lower health care costs • Innova pilot program announced in August 2018 2 Publish pharmacoeconomic benefits when providers use the PE
Slide 17: Capitalization & Balance Sheet
Investor Presentation 17 CAPITALIZATION & BALANCE SHEET Common Stock Issued and Outstanding (8/10/18) 6,284,097 Series A Preferred 550,000 Series A - 1 Preferred 500,000 Total Shares of Common Stock Underlying Issued Options 887,998 Weighted Average Strike Price: $10.49 Total Shares of Common Stock
Slide 18: Summary
Investor Presentation 18 SUMMARY With telemedicine, we can deliver mental health services where and when the patient needs them including the privacy of one’s own home. With artificial intelligence, machine learning and data analytics, we can analyze massive quantities of data to recognize patterns,
Slide 19: Contact
Investor Presentation 19 CONTACT Robin L. Smith, MD, MBA, Chairman of the Board tel : 917 - 691 - 7409 email: robin@robinlsmith.com George C. Carpenter IV, President and Chief Executive Officer tel: 949 - 697 - 2161 email: gcarpenter@myndanalytics.com Don D’Ambrosio, Chief Financial Officer tel : 94
Slide 20: Healthcare AI Market
Investor Presentation HEALTHCARE AI MARKET • According to Accenture, when combined, key clinical health artificial intelligence (AI) applications can potentially create $150 billion in annual savings for the United States healthcare economy by 2026 1 • In just the next five years, the health AI mark
Slide 21: Interim Findings from the 4th Clinical Trial - Walter Reed PEER Trial
Investor Presentation 5 2 Peer Followed Standard of Care 144% 75% 75% 139% Depression SuicidalityGlobal Improvement PTS P e r c e n t 21 INTERIM FINDINGS FROM THE 4 TH CLINICAL TRIAL – WALTER REED PEER TRIAL Patients whose physicians followed PEER had more statistically significant improvement than
Slide 22: Independent Validation
Investor Presentation 22 INDEPENDENT VALIDATION From a rapidly growing research base, 100 peer - reviewed studies* of Quantitative EEG (QEEG) neurometrics (n = 6,025) have demonstrated the utility of these markers, including: • 12 randomized controlled trials of QEEG neurometrics for predicting medi
Slide 23: Digital Health Care: 2016 Largest Acquisitions
Investor Presentation Source: RockHealth, 2016 https:// rockhealth.com /reports/digital - health - exits - 2016 - ytd - 112 - digital - health - acquisitions - and - two - ipos/. DIGITAL HEALTH CARE In 2016 the 10 largest acquisitions brought in over $11B for shareholders 23 Target Acquired By Acqui
Slide 24: Mental Health - Incidence & Cost
Investor Presentation 24 MENTAL HEALTH - INCIDENCE & COST • Globally, an estimated 3 0 0 million people suffer from depression and 60 million have Bipolar affective disorder . (1) • Anxiety disorders are the most common mental illness in the U.S. affecting 40 million adults. (2) • It is estimated th
Slide 25: Economic Impact (in 2012)
Investor Presentation Source: Melek S., Norris D., Paulus J.: Economic Impact of Integrated Medical - Behavioral Healthcare: Implications for Psychiatry. Prepared for APA; 2014, pp.1 - 39. 25 ECONOMIC IMPACT (IN 2012) Population % with Behavioral Health (BH) Diagnosis Per - member per - month (PMPM)
Slide 26: Problem and Solution: Service Lines
Investor Presentation Problem Looming crisis in access to care: • Psychiatrist shortage • Waiting lists are high • 70% of mental health is treated by PCPs • Low attendance and adherence to treatment (avg = 2 visits) Clinicians often rely on trial and error prescribing for depression, anxiety, PTSD a
Slide 27: Trial and Error Pharmacotherapy
Investor Presentation 27 Thomas R. Insel, MD 2009 - 2010 “ Current medications are not sufficient for most patients... We still do not know who will respond to a specific treatment. Even for the fraction of patients who ultimately respond, clinicians often must resort to trial and error before findi
MYnd Analytics — Investor Presentation (September 2018) on 6ix